08.06.2016 Views

LATAM Adalimumab Market

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Browse Full Research Report on <strong>LATAM</strong> <strong>Adalimumab</strong> <strong>Market</strong>:<br />

http://www.transparencymarketresearch.com/latam-adalimumab-market.html<br />

The rheumatoid arthritis application segment held the biggest share in the Latin American<br />

adalimumab market due to extensive research on the subject, increasing acceptance of<br />

adalimumab for treating rheumatoid arthritis, and improving diagnosis of the health condition at<br />

lab levels. A research paper published by Reumatologia Clinica Journal in 2013, titled ‘Current<br />

Therapies in Rheumatoid Arthritis,’ shows that the use of TNF inhibitors such as adalimumab for<br />

treating rheumatoid arthritis is extremely common.<br />

The paper also highlights that the growing incidence of this disease will accelerate the usage of<br />

adalimumab. The factors restraining the growth of the adalimumab market in Latin America are<br />

the risks of infections and possible side effects posed by these medications. However, the<br />

demand of adalimumab for treating psoriasis will offset this negative effect in the near future.<br />

The Latin America adalimumab market will also be positively influenced by the growing<br />

healthcare expenditure and growing preference for biologic drugs in the region. Some of the<br />

important players operating in the Latin American adalimumab market are Boehringer Ingelheim<br />

GmbH, Pfizer, Inc., AbbVie, Inc. Amgen, Inc., Mylan N.V., and Novartis AG.<br />

In the current market scenario, the majority of the players are trying to develop adalimumab<br />

biosimilars that will treat psoriasis and rheumatoid arthritis. The ongoing clinical trials for<br />

ensuring the safety and efficacy of these biosimilars are a testimony to this fact. This R&D<br />

avenue is expected to retain an important place in the adalimumab market in Latin America in<br />

the coming years.<br />

Browse Full Press Release on <strong>LATAM</strong> <strong>Adalimumab</strong> <strong>Market</strong>:<br />

Press Release<br />

About Us<br />

Transparency <strong>Market</strong> Research (TMR) is a global market intelligence company providing<br />

business information reports and services. The company’s exclusive blend of quantitative<br />

forecasting and trend analysis provides forward-looking insight for thousands of decision<br />

makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data<br />

sources and various tools and techniques to gather and analyze information.<br />

TMR’s data repository is continuously updated and revised by a team of research experts so that<br />

it always reflects the latest trends and information. With extensive research and analysis<br />

capabilities, Transparency <strong>Market</strong> Research employs rigorous primary and secondary research<br />

techniques to develop distinctive data sets and research material for business reports.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!